Johnson & Johnson JNJ
NYSE JNJ
$270.24 +2.87 (+1.07%)
At close: Aug 21, 2026 · 4:00 PM EDT

Johnson & Johnson (JNJ) Cash from Investing Activities (2009 - 2026)

Johnson & Johnson (JNJ) posted Cash from Investing Activities of -$1.1 billion for Q2 2026, down 6.73% sequentially from -$1.0 billion in Q1 2026, and up 93.92% YoY from -$572.4 million in Q2 2025.

Johnson & Johnson (JNJ) Cash from Investing Activities (2009 - 2026) Analysis & Trends

Johnson & Johnson has reported Cash from Investing Activities for 18 years, with the latest figure at -$1.1 billion in Q2 2026.

  • Quarterly Cash from Investing Activities rose 93.92% year-over-year to -$1.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$7.2 billion (up 68.81% YoY) and the FY2025 annual result came in at -$23.6 billion, down 26.82% from the prior year.
  • Cash from Investing Activities declined to -$1.1 billion in Q2 2026 per JNJ's latest filing, from -$1.0 billion in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $3.3 billion in Q2 2023 and troughed at -$18.3 billion in Q2 2025.
  • A 5-year average of -$3.5 billion and a median of -$1.3 billion in 2023 frame the typical range for Cash from Investing Activities.
  • The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities plunged 1864.32% in 2022, then jumped 191.22% in 2023.
  • Over 5 years, Cash from Investing Activities stood at -$3.6 billion in 2022, then jumped by 66.92% to -$1.2 billion in 2023, then decreased by 9.82% to -$1.3 billion in 2024, then sank by 239.77% to -$4.5 billion in 2025, then surged by 75.25% to -$1.1 billion in 2026.
  • According to Business Quant data, Cash from Investing Activities over the past three periods registered -$1.1 billion, -$1.0 billion, and -$4.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn -1.11 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn -1.20 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn -5.60 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn -3.11 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn -2.91 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn -569.00 Mn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn -10.35 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn 2.11 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn 2.68 Bn
10 Sanofi 55.07 Bn 47.69 Bn 10.79 Bn -424.26 Mn

Historic Data

Download Data
DateValue
Jun 28, 2026 -1.11 Bn
Jun 28, 2026 -1.11 Bn
Mar 29, 2026 -1.04 Bn
Mar 29, 2026 -1.04 Bn
Dec 28, 2025 -4.49 Bn
Dec 28, 2025 -4.49 Bn
Sep 28, 2025 -542.00 Mn
Sep 28, 2025 -542.00 Mn
Jun 29, 2025 -18.26 Bn
Jun 29, 2025 -18.26 Bn
Mar 30, 2025 -297.00 Mn
Mar 30, 2025 -297.00 Mn
Dec 29, 2024 -1.32 Bn
Dec 29, 2024 -1.32 Bn
Sep 29, 2024 -3.13 Bn
Sep 29, 2024 -3.13 Bn
Jun 30, 2024 -13.69 Bn
Jun 30, 2024 -13.69 Bn
Mar 31, 2024 -464.00 Mn
Mar 31, 2024 -464.00 Mn